Skip Navigation

Annals of Oncology 2006 17(2):181; doi:10.1093/annonc/mdj144
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Cost – utility of aromatase inhibitors
 
Several studies have shown aromatase inhibitors administered as monotherapy or sequentially to tamoxifen to improve relapse-free survival in postmenopausal women with early breast cancer. However, we lack information on whether there could be any differences with respect to efficacy and toxicity between the different drugs or related to regimen of administration. In this setting, any difference regarding cost/utility may be an important issue when selecting regimen. In this . . . [Full Text of this Article]


   Early versus delayed chemotherapy in mesothelioma
 

   AML in elderly patients not eligible for intensive chemotherapy
 

   Effects of smoking regulations in Italy
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?